Fecal transplant to clear resistant gut bacteria
Part of Infections clinical trials.
This Phase 3 study tests whether a fecal microbiota transplant (FMT) can eliminate hard-to-treat bacteria in the gut, such as ESBL or carbapenem-resistant bacteria. If it works, it may reduce future infections and antibiotic-resistant illness.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 to under 105 years old
- You have proof from a rectal swab or recent test of resistant gut bacteria (ESBL-E or CRE), or a recent ESBL-E/CRE infection in the last year (for ESBL carriers, that recent infection is required)
- If you are assigned to take treatment by mouth, you must be able to swallow 50 capsules in a day with no swallowing problems
- You cannot currently be on antibiotics, except long-term antibiotic prevention (at least 3 months in a year)
- You must not be in the intensive care unit (ICU), and you must not be pregnant or breastfeeding
- You must be able to follow study rules (birth control if needed, no other treatment trials, and consent to participate)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at a treatment made from stool donors (called fecal microbiome therapy) to help remove carbapenem-resistant gut bacteria in the body. It’s mainly for adults who recently tested positive for these bacteria on a rectal swab, and it checks whether the therapy can help eradicate the germs.
This study tests a stool-based treatment (fecal microbiota treatment) to help remove “carbapenem-resistant” bacteria living in the gut. If you carry these bacteria without being sick, the goal is to reduce or stop that colonization.
This trial tests whether giving healthy bacteria through capsules (a fecal transplant) can help get rid of CRE, a type of bacteria that is hard to treat because it resists many antibiotics. If successful, this could reduce the risk of serious infections.
This Phase 1/2 study tests whether a fecal microbiome transplant (FMT) can reduce active inflammation in people with Crohn’s disease. It’s designed for people who currently have signs of active bowel inflammation and can attend regular procedure visits.
This trial tests whether a fecal microbiota transplantation (FMT), which transfers healthy bacteria from a donor into your gut, can reduce severe irritable bowel syndrome (IBS) symptoms. FMT is being studied as a possible new treatment for people with IBS that hasn't improved with other treatments.
This trial tests whether a fecal transplant can remove multidrug-resistant bacteria from the gut, potentially reducing the risk of infections. It may help patients who carry these bacteria without symptoms.
Hear when a new Enterobacteriaceae Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.